Sylvester Stallone TRT: A Clinical Interpretation of His Hormone Therapy

What Sylvester Stallone Has Said About TRT

Stallone has been candid about testosterone use in multiple interviews spanning more than two decades. His disclosures are specific enough to provide a clinical starting point.

His Own Words

In a 2008 interview with Time magazine, Stallone stated: "Everyone over 40 years old would be wise to investigate it [testosterone and HGH] because it really is remarkable." He has repeated similar sentiments in podcast appearances and press junkets, consistently framing TRT as a performance and quality-of-life measure rather than strictly a medical treatment for diagnosed disease.

In a later interview with FHM Australia, Stallone was reported saying he used testosterone "for 12 years" as of the interview date, placing the start of his use in the early-to-mid 1990s, when he was in his mid-to-late 40s. He did not publicly disclose his lab values, specific formulation, or prescribing physician.

The 2007 Australian Incident

Australian customs officials confiscated 48 vials of Jintropin (somatropin, a recombinant human growth hormone) from Stallone's luggage in February 2007. He pleaded guilty to importing a controlled substance and paid a fine of AUD 10,400. Testosterone was not the subject of that charge. The distinction matters clinically. HGH and testosterone are separate compounds with different regulatory pathways, different evidence bases, and different risk profiles. The 2007 case involved HGH, not TRT directly, though Stallone confirmed using both at various points.

Clinical Context: Why Men Over 50 Seek TRT

Age-related testosterone decline is well-documented. A 2001 analysis published in the Journal of Clinical Endocrinology and Metabolism (Harman et al., N=890 men followed over 8.6 years) found total testosterone declined at approximately 0.4% per year and free testosterone at 1.2% per year from the third decade onward [1]. By age 70, roughly 30% of men meet biochemical criteria for hypogonadism [2].

Symptoms That Drive Evaluation

The American Urological Association (AUA) defines hypogonadism as a total serum testosterone below 300 ng/dL confirmed on two morning measurements, combined with at least one symptom [3]. Symptoms include reduced libido, erectile dysfunction, fatigue, depressed mood, decreased muscle mass, and increased adiposity.

Stallone has publicly cited energy, recovery, and physical conditioning as motivations. Those align precisely with the symptom categories recognized in the AUA's 2018 guideline on testosterone deficiency [3].

Population-Level Prevalence

The Boston Area Community Health (BACH) survey estimated that 5.6% of U.S. Men aged 30 to 79 have symptomatic androgen deficiency [4]. That figure rises steeply with age. Among men aged 70 to 79 in the European Male Ageing Study (N=3,369), the prevalence of late-onset hypogonadism with both biochemical and symptomatic criteria reached 2.1%, though biochemical-only prevalence was substantially higher [5].

FDA-Approved TRT Formulations: What Is Likely and What Is Available

Stallone has not publicly named a specific formulation. Clinically, men with his profile (high activity level, desire for stable hormone levels, access to concierge medicine) are often prescribed one of three options.

Intramuscular Testosterone

Testosterone cypionate and testosterone enanthate are the most commonly prescribed injectable forms in the United States. Typical dosing is 100 to 200 mg administered every one to two weeks, or 50 to 100 mg weekly to reduce peak-trough fluctuation. The FDA approved testosterone cypionate injection (Depo-Testosterone) for male hypogonadism decades ago; the current label is available at accessdata.fda.gov [6].

Weekly injections produce more stable serum levels than biweekly dosing. A pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism (Snyder et al.) demonstrated that 200 mg testosterone enanthate every two weeks produces peaks exceeding 1,500 ng/dL and troughs falling below 300 ng/dL, a swing that may worsen mood variability [7].

Transdermal Gels and Patches

Testosterone gel 1% (AndroGel) and 1.62% (AndroGel 1.62%) deliver 40.5 to 81 mg/day transdermally. The TRAVERSE trial used testosterone gel as the study drug.

Subcutaneous Pellets

Testosterone pellets (Testopel) are implanted subcutaneously under local anesthesia every three to six months. Pellets appeal to patients who prefer to avoid daily or weekly administration.

What the TRAVERSE Trial Actually Shows

The TRAVERSE trial is the largest cardiovascular safety trial of testosterone therapy to date. Published in the New England Journal of Medicine in 2023 (N=5,204, median follow-up 33 months), it compared testosterone gel 1.62% to placebo in men aged 45 to 80 with hypogonadism and either pre-existing cardiovascular disease or elevated CV risk [8].

Cardiovascular Findings

The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The incidence was 7.0% in the testosterone group versus 7.3% in the placebo group (hazard ratio 0.96, 95% CI 0.78 to 1.17), meeting non-inferiority criteria. Testosterone did not increase major adverse cardiovascular events in this population [8].

A secondary finding drew attention: atrial fibrillation was more common in the testosterone group (3.5% vs. 2.4%, P<0.001) [8]. Clinicians should factor this into risk assessment for patients with pre-existing arrhythmia history.

Efficacy Signals

Sexual activity scores, sexual desire, and erectile function all improved significantly in the testosterone arm versus placebo at 12 months (P<0.001 for each) [8]. Lean mass increased and fat mass decreased. These findings support the biological plausibility of the benefits Stallone has described.

Bone Density

A substudy of TRAVERSE confirmed that testosterone increased lumbar spine bone mineral density by 3.5% and femoral neck BMD by 2.9% at 24 months versus placebo [9]. For men in their 70s, fracture risk reduction is a meaningful clinical outcome, separate from the cosmetic and performance reasons that typically make headlines.

TRT Risks: What a Prescribing Physician Weighs

No therapy is without tradeoff. Responsible TRT prescribing requires monitoring and patient-specific risk stratification.

Erythrocytosis

Testosterone stimulates erythropoiesis. Hematocrit above 54% is a dose-limiting toxicity and an independent risk factor for thrombotic events. The Endocrine Society's 2018 clinical practice guideline recommends checking hematocrit at baseline, at three months, and then annually; dose reduction or phlebotomy is indicated if hematocrit exceeds 54% [10].

Fertility Suppression

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and impairing spermatogenesis. Men who want to preserve fertility should not use conventional TRT. Alternatives include clomiphene citrate (off-label) or human chorionic gonadotropin (hCG) to stimulate endogenous production [11].

Prostate Safety

The TRAVERSE trial found no statistically significant increase in prostate cancer incidence over 33 months [8]. However, TRT is contraindicated in men with known or suspected prostate cancer. The Endocrine Society guideline recommends checking PSA at three to six months after initiation and annually thereafter [10].

Skin Transfer Risk

Gel formulations carry a small but real risk of transferring testosterone to female partners or children through skin contact. FDA labeling for AndroGel carries a black-box warning for this reason [6].

HGH Versus TRT: Separating the Two Therapies

Because Stallone's most publicized legal incident involved HGH, a brief comparison is warranted.

Different Mechanisms

Testosterone is an androgen that binds intracellular androgen receptors, directly affecting gene transcription in muscle, bone, brain, and reproductive tissue. Human growth hormone acts through IGF-1 signaling on a distinct receptor pathway. The two are not interchangeable, and their risk profiles differ substantially.

Evidence Base Differs Sharply

TRT has multiple large randomized controlled trials and FDA-approved indications for male hypogonadism. The evidence base for HGH in non-deficient adults is far weaker. A 2007 meta-analysis in the Annals of Internal Medicine (Liu et al., 31 trials, N=220 adults) found that HGH in healthy older adults increased lean mass and decreased fat mass but did not improve functional outcomes and caused significant rates of soft-tissue edema, arthralgias, and carpal tunnel syndrome [12]. The FDA has not approved HGH for anti-aging or athletic performance enhancement.

What a Clinician Would Want to Know Before Starting TRT in a 50+ Male

Starting TRT without proper evaluation is a clinical error. The AUA 2018 guideline specifies a minimum workup [3].

Required Lab Evaluation

Two fasting morning total testosterone measurements (collected between 7 a.m. And 10 a.m.) are required to confirm deficiency. A single low value is insufficient. Additional labs include LH, FSH, prolactin, complete blood count, PSA, and a metabolic panel [3].

Differential Diagnosis Before Prescribing

Low testosterone has secondary causes that must be ruled out first. These include pituitary adenoma (check LH, FSH, prolactin, and MRI if indicated), hemochromatosis, obstructive sleep apnea, obesity-related hypogonadism, and opioid-induced androgen deficiency. Treating the underlying cause may normalize testosterone without exogenous therapy [10].

Monitoring Schedule

The Endocrine Society recommends follow-up testosterone levels at three months (targeting mid-normal range, approximately 400 to 700 ng/dL), then every six to twelve months once stable. PSA, hematocrit, and symptom review accompany each monitoring visit [10].

The Broader Picture: TRT as a Mainstream Option for Older Men

Stallone's openness about TRT, whatever one thinks of celebrity health disclosures, has contributed to a cultural shift. Testosterone therapy prescriptions in the United States increased more than threefold between 2001 and 2011 before partially declining after cardiovascular concerns surfaced in 2013 to 2014 [13]. The TRAVERSE data have partially rehabilitated the therapy's cardiovascular reputation for appropriately selected patients.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men aged 65 and older with low testosterone (N=790, published in NEJM 2016), showed that testosterone improved sexual function, physical activity (as measured by 6-minute walk distance), and bone density, though it did not improve vitality scores as a primary endpoint [14].

The Endocrine Society's 2018 guideline states: "We recommend testosterone therapy for men with classic androgen deficiency syndromes to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density" [10]. That statement covers most of the outcomes Stallone has publicly attributed to his own therapy.

Practical Takeaways for Men Considering TRT

Age alone is not an indication. Symptoms plus confirmed biochemical deficiency on two separate morning draws are required under current guidelines [3].

Get a proper workup. Self-treating or using testosterone obtained outside the medical system carries real risks: undetected prostate cancer, untreated secondary causes, unmonitored hematocrit elevation, and cardiovascular events.

Choose a formulation matched to lifestyle. Weekly subcutaneous or intramuscular injections offer the most precise dosing control and the lowest cost. Daily gels offer convenience but require care to avoid skin transfer.

Monitor consistently. Hematocrit, PSA, and testosterone levels at three months and annually are the minimum standard [10].

Men with a history of prostate cancer, breast cancer, untreated polycythemia, severe lower urinary tract symptoms, uncontrolled heart failure, or desire for fertility should not use standard TRT protocols [3].